SEC Form 4 · accession 0001638599-17-000229
AYTU BIOPHARMA, INC · AYTU
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Joshua R. Disbrow
Officer — Chief Executive Officer · Director
Period of report
Feb 27, 2017
Accepted (ET)
Mar 1, 2017 · 6:41 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001385818
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 27, 2017 | M | 187,500 | $0.75 | A | 630,194 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Warrant to Purchase Common Stock | $1.86 | Feb 27, 2017 | M | 166,666 | D | Nov 2, 2017 | Nov 2, 2021 | Common Stock | 166,666 | 0 | D |
| Warran to Purchase Common Stock | $6.00 | Feb 27, 2017 | M | 20,834 | D | May 6, 2016 | May 6, 2021 | Common Stock | 20,834 | 0 | D |
| Warrant to Purchase Common Stock | $6.00 | holding | — | — | — | Dec 16, 2016 | May 6, 2021 | Common Stock | 28,924 | 28,924 | D |
| Employee Stock Option GrantF3 | $3.23 | holding | — | — | — | — | Nov 11, 2025 | Common Stock | 50,000 | 50,000 | D |
| Employee Stock Option GrantF2 | $3.23 | holding | — | — | — | — | Jul 7, 2026 | Common Stock | 60,000 | 60,000 | D |
Explanation of responses
- F1Of these shares, 190,000 are restricted shares that vest on July 7, 2026, subject to earlier vesting in certain situations.
- F233.3% vests on July 7, 2017, 33.3% vests on July 7, 2018 and 33.4% on July 7, 2019, subject to the Grantee's continued service as an employee on such dates.
- F333.3% vests on November 11, 2016, 33.3% vests on November 11, 2017 and 33.4% vests on November 11, 2018, subject to the Grantee's continued service as an employee on such dates.